tbuckley/cabot-search huggingface dataset:
Robotic Platform Use in General Thoracic Surgery
Authors: M. Blair Marshall, Jon O. Wee
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Near‐Infrared Spectroscopy Reveals Brain Hypoxia and Cerebrovascular Dysregulation in Primary Biliary Cholangitis
Authors: Chris C. Duszynski, V. Avati, A.P. Lapointe, F. Scholkmann, J.F. Dunn, M.G. Swain
Journal: Hepatology (2019)

Background and Aims Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease linked to symptoms including fatigue and altered mood/cognition, indicating that chronic liver inflammation associated with PBC can impact brain function. We employed near‐infrared spectroscopy (NIRS), a noninvasive neuroimaging technique, to determine whether patients with PBC exhibit reduced cerebral oxygen saturation (StO 2 ) and altered patterns of microvascular cerebral blood perfusion and whether these alterations were associated with clinical phenotype. This observational case–control study was conducted at a tertiary hospital clinic (University of Calgary Liver Unit). Approach and Results Thirteen female patients with noncirrhotic PBC, seven female patients with cirrhotic PBC, and 11 healthy female controls were recruited by physician referral and word of mouth, respectively. NIRS was used to measure cerebral hemoglobin and oxygen saturation. A wavelet phase coherence method was used to estimate the coherent frequency coupling of temporal changes in cerebral hemodynamics. The PBC group demonstrated significantly reduced cerebral StO 2 ( P = 0.01, d = 0.84), indicating cerebral hypoxia, significantly increased cerebral deoxygenated hemoglobin concentration ( P &lt; 0.01, d = 0.86), and significantly reduced hemodynamic coherence in the low‐frequency band (0.08‐0.15 Hz) for oxygenated hemoglobin concentration ( P = 0.02, d = 0.99) and total hemoglobin (tHb) concentration ( P = 0.02, d = 0.50), indicating alterations in cerebrovascular activity. Complete biochemical response to ursodeoxycholic acid (UDCA) therapy in early patients with PBC was associated with increased cerebral tHb concentration and decreased hemodynamic coherence. Conclusions Using NIRS, patients with PBC were found to have hypoxia, increased cerebral hemoglobin concentration, and altered cerebrovascular activity, which were reversed in part in UDCA responders. In addition, symptoms and quality‐of‐life measures did not correlate with brain hypoxia or cerebrovascular dysregulation in patients with PBC.
Abstract P036: Effects of Exercise Training and Increasing Non-Exercise Physical Activity on Lipoprotein Subclass and Size: Results From the I-CAN Study
Authors: Damon L Swift, Mark A Sarzynski, Joshua McGee, Savanna Barefoot, Patricia M Brophy, Tyara Nevels, Lesley Lutes, Joseph Houmard
Journal: Circulation (2018)

Introduction: Previous studies have shown that lipoprotein particle size and lipoprotein subclasses are associated with cardiovascular and type 2 diabetes risk, and have independent prognostic value above traditional lipid concentrations. The impact of exercise training and increasing non-exercise physical activity on lipoprotein subclasses and size has not been previously investigated. Methods: In this pilot study, 35 obese adults were randomized to aerobic exercise training (50-75% of VO 2 max) (AERO, n=11), aerobic training and increasing non-exercise physical activity (AERO-PA, n=10, ~3,000 steps above baseline levels), or a non-exercise control group (n=14) for 6 months. Baseline and follow-up blood samples were analyzed for lipoprotein subclass, size, and lipoprotein insulin resistance score (LP-IR) using nuclear magnetic resonance spectroscopy (Liposcience, NC). Analysis of covariance was used to evaluate the change in outcome variables following the intervention across groups with adjustment for baseline value and age. Participants who changed lipid medications during the intervention (n=2) or who were non-adherent to exercise training (n=2) were excluded from the analysis. Results: Significant reductions were observed for mean VLDL size in the AERO-PA group (-4.7 nm, CI: -8.7 to -0.8) compared to control group (0.7 nm, CI: -2.7 to 4.4) and the AERO group (1.1 nm, CI: -2.9 to 5.0). Reductions in triglyceride concentrations were observed in the AERO-PA group (-28.3 mg/dL, CI: -50.3 to -6.4) compared to control (4.1 mg/dL, CI: -14.6 to 22.8). Additionally, we observed a trend for LP-IR index (p=0.055) and the concentration of small HDL particles (p=0.093) to decrease in the AERO-PA group compared to controls, with no differences compared to the AERO group (p&gt;0.10). No significant changes were observed for other notable lipoprotein measures, such as LDL size, HDL size, concentration of small LDL particles, or chylomicron measures (p&gt;0.05). In the AERO-PA group, the change in steps was associated with the change in LP-IR index (r= -0.71, p=0.013), but not with change in VLDL size (r= -0.24, p=0.463) or triglyceride concentrations (r=-0.28, p=0.388). Conclusions: Aerobic training combined with increasing non-exercise physical activity leads to favorable changes in the lipoprotein profile, specifically reductions in VLDL size and triglycerides, and may have promise for other lipoprotein traits (reductions in LP-IR and small HDL particles) that were not observed with aerobic training alone.
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
Authors: Lynda Vuong, Ritesh R. Kotecha, Martin H. Voss, A. Ari Hakimi
Journal: Cancer Discovery (2019)

Abstract Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer comparisons. Features of the tumor microenvironment heavily affect disease biology and may affect responses to systemic therapy. With evolving frontline options in the metastatic setting, several immune checkpoint blockade regimens have emerged as efficacious, and there is growing interest in characterizing features of tumor biology that can reproducibly prognosticate patients and/or predict the likelihood of their deriving therapeutic benefit. Herein, we review pertinent characteristics of the tumor microenvironment with dedicated attention to candidate prognostic and predictive signatures as well as possible targets for future drug development. Significance: Tumor microenvironment features broadly characterizing angiogenesis and inflammatory signatures have shown striking differences in response to immune checkpoint blockade and antiangiogenic agents. Integration of stromal and immune biomarkers may hence produce predictive and prognostic signatures to guide management with existing regimens as well as future drug development.
Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)
Authors: Nizar J. Bahlis, Heather Sutherland, Darrell J White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina J. Gasparetto, Gary J Schiller, Richard LeBlanc, William Bensinger, Brea Lipe, Aldo Del Col, Michael G. Kauffman, Sharon Shacham, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Christine I Chen
Journal: Blood (2017)
Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids As Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease
Authors: Natasha Kekre, Haesook T Kim, Vincent T Ho, Yikun Guo, Umair Mahmood, Wafae Belatreche, John Koreth, Philippe Armand, Sarah Nikiforow, Edwin Alyea, Prashant Nageshwar, Brett Glotzbecker, Areej El-Jawahri, Robert J. Soiffer, Joseph H. Antin, Yi-Bin Chen, Corey S. Cutler
Journal: Blood (2017)
Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL)
Authors: CarloBriguori, FlavioAiroldi, DavideD’Andrea, ErminioBonizzoni, NucciaMorici, AmeliaFocaccio, IassenMichev, MatteoMontorfano, MauroCarlino, JohnCosgrave, BrunoRicciardelli, AntonioColombo
Journal: Circulation (2007)

Background— Volume supplementation by saline infusion combined with N-acetylcysteine (NAC) represents an effective strategy to prevent contrast agent–induced nephrotoxicity (CIN). Preliminary data support the concept that sodium bicarbonate and ascorbic acid also may be effective in preventing CIN. Methods and Results— Three hundred twenty-six consecutive patients with chronic kidney disease, referred to our institutions for coronary and/or peripheral procedures, were randomly assigned to prophylactic administration of 0.9% saline infusion plus NAC (n=111), sodium bicarbonate infusion plus NAC (n=108), and 0.9% saline plus ascorbic acid plus NAC (n=107). All enrolled patients had serum creatinine ≥2.0 mg/dL and/or estimated glomerular filtration rate <40 mL · min−1 · 1.73 m−2. Contrast nephropathy risk score was calculated in each patient. In all cases, iodixanol (an iso-osmolar, nonionic contrast agent) was administered. The primary end point was an increase of ≥25% in the creatinine concentration 48 hou...
Transplant First, Dialysis Last
Authors: Abhijit V. Kshirsagar, Melina R. Kibbe, David A. Gerber
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract #552: Identification of differentially expressed microRNAs based on esophageal cancer signatures
Authors: Masayuki Kano, Isamu Hoshino, Haruhito Sakata, Yasunori Akutsu, Takanori Nishimori, Kentaro Murakami, Akihiro Usui, Jun Tsukada, Naohiko Seki, Yoshihiro Nabeya, Hisahiro Matsubara
Journal: Cancer Research (2009)

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive and lethal malignancies in the world. Patients with ESCC are very poor prognosis because most cases are not diagnosed until the disease is at advanced stage. The understanding of the new molecular pathways of ESCC carcinogenesis would be helpful in improving diagnosis and therapy of the disease. MicroRNA(miRNA) are endogenous short non-coding RNA molecules, which regulate gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner. Growing evidence has suggested that miRNAs are aberrantly expressed in many human cancers and they may play significant roles in carcinogenesis and progression of cancer. MiRNA over-expression could result in down-regulation of tumor suppressor genes, whereas their under-expression could lead to oncogenes activation. A few studies of the relationship between miRNAs and ESCC have been reported, but the functions of each miRNAs in ESCC are still unknown absolutely. In the present study, we examined differentially expressed miRNAs in ESCC specimens and identified differentially expressed miRNAs from head and neck squamous cell cancer expression signatures. These specimens were obtained from patients in the Chiba University hospital, Japan from 2003 to 2007 with informed consent and agreement. In all the samples, clinicopathological information (age, gender, pathology, differentiation, TNM classification, tumor stage, and survival time after surgery) was available. In this study, we identified 14 up-regulated mature miRNAs and 15 down-regulated mature miRNAs. Transient transfection of down-regulated miRNAs (such as miR-504, miR-145, miR-1, miR-375, and miR-326) inhibited cell growth in cancer cell line. These miRNAs might play tumor suppressor role in the proliferative process of the ESCC. To search target genes of miR-504, combining experimental and bioinformatics data identified several cancer-related genes. Our miRNA expression signatures and identification of target genes may provide an understanding of the potential mechanisms in ESCC carcinogenesis.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 552.
Circulating Tumor Cell-Neutrophil Tango along the Metastatic Process
Authors: Massimo Saini, Barbara M. Szczerba, Nicola Aceto
Journal: Cancer Research (2019)

The crosstalk between cancer cells and the immune system is crucial for disease progression and its therapeutic targeting is providing exciting results, in particular with newly developed immune checkpoint inhibitors. Current approaches primarily focus on cellular interactions occurring between tumor cells and T lymphocytes; however, recent data highlight a crucial role of neutrophils in support of tumor progression and suggest yet unexplored treatment opportunities. In this review, we summarize the current understanding of those interactions that occur between neutrophils and cancer cells, focusing on both protumor and antitumor activities of neutrophils at different stages of cancer progression. These include infiltration of neutrophils into the primary tumor, their interactions with circulating tumor cells (CTC) within the bloodstream, and their involvement in the establishment of a metastatic niche. Additionally, we discuss how further investigation of CTCs and their interacting immune cell partners may point towards novel immune checkpoint inhibition strategies and provide new insights on the efficacy of already existing immunotherapies.
Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity
Authors: Nathan W. Zammit, Owen M. Siggs, Paul E. Gray, Keisuke Horikawa, David B. Langley, Stacey N. Walters, Stephen R. Daley, Claudia Loetsch, Joanna Warren, Jin Yan Yap, Daniele Cultrone, Amanda Russell, Elisabeth K. Malle, Jeanette E. Villanueva, Mark J. Cowley, Velimir Gayevskiy, Marcel E. Dinger, Robert Brink, David Zahra, Geeta Chaudhri, Gunasegaran Karupiah, Belinda Whittle, Carla Roots, Edward Bertram, Michiko Yamada, Yogesh Jeelall, Anselm Enders, Benjamin E. Clifton, Peter D. Mabbitt, Colin J. Jackson, Susan R. Watson, Craig N. Jenne, Lewis L. Lanier, Tim Wiltshire, Matthew H. Spitzer, Garry P. Nolan, Frank Schmitz, Alan Aderem, Benjamin T. Porebski, Ashley M. Buckle, Derek W. Abbott, John B. Ziegler, Maria E. Craig, Paul Benitez-Aguirre, Juliana Teo, Stuart G. Tangye, Cecile King, Melanie Wong, Murray P. Cox, Wilson Phung, Jia Tang, Wendy Sandoval, Ingrid E. Wertz, Daniel Christ, Christopher C. Goodnow, Shane T. Grey
Journal: Nature Immunology (2019)
Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia
Authors: Bijina Balakrishnan, Ding An, Vi Nguyen, Christine DeAntonis, Paolo G.V. Martini, Kent Lai
Journal: Molecular Therapy (2019)

Classic galactosemia (CG) is a potentially lethal inborn error of galactose metabolism that results from deleterious mutations in the human galactose-1 phosphate uridylyltransferase (GALT) gene. Previously, we constructed a GalT−/− (GalT-deficient) mouse model that exhibits galactose sensitivity in the newborn mutant pups, reduced fertility in adult females, impaired motor functions, and growth restriction in both sexes. In this study, we tested whether restoration of hepatic GALT activity alone could decrease galactose-1 phosphate (gal-1P) and plasma galactose in the mouse model. The administration of different doses of mouse GalT (mGalT) mRNA resulted in a dose-dependent increase in mGalT protein expression and enzyme activity in the liver of GalT-deficient mice. Single intravenous (i.v.) dose of human GALT (hGALT) mRNA decreased gal-1P in mutant mouse liver and red blood cells (RBCs) within 24 h with low levels maintained for over a week. Repeated i.v. injections increased hepatic GalT expression, nearly normalized gal-1P levels in liver, and decreased gal-1P levels in RBCs and peripheral tissues throughout all doses. Moreover, repeated dosing reduced plasma galactose by 60% or more throughout all four doses. Additionally, a single intraperitoneal dose of hGALT mRNA overcame the galactose sensitivity and promoted the growth in a GalT−/− newborn pup. Classic galactosemia (CG) is a potentially lethal inborn error of galactose metabolism that results from deleterious mutations in the human galactose-1 phosphate uridylyltransferase (GALT) gene. Previously, we constructed a GalT−/− (GalT-deficient) mouse model that exhibits galactose sensitivity in the newborn mutant pups, reduced fertility in adult females, impaired motor functions, and growth restriction in both sexes. In this study, we tested whether restoration of hepatic GALT activity alone could decrease galactose-1 phosphate (gal-1P) and plasma galactose in the mouse model. The administration of different doses of mouse GalT (mGalT) mRNA resulted in a dose-dependent increase in mGalT protein expression and enzyme activity in the liver of GalT-deficient mice. Single intravenous (i.v.) dose of human GALT (hGALT) mRNA decreased gal-1P in mutant mouse liver and red blood cells (RBCs) within 24 h with low levels maintained for over a week. Repeated i.v. injections increased hepatic GalT expression, nearly normalized gal-1P levels in liver, and decreased gal-1P levels in RBCs and peripheral tissues throughout all doses. Moreover, repeated dosing reduced plasma galactose by 60% or more throughout all four doses. Additionally, a single intraperitoneal dose of hGALT mRNA overcame the galactose sensitivity and promoted the growth in a GalT−/− newborn pup.
Prognostic value of the <i>EGFR</i> gene amplification by chromogenic in situ hybridization (CISH) in adult patients with glioblastoma.
Authors: Santiago Rafael Bella, Ricardo Alejandro Theaux, Alejo Lingua, Jose Roberto Llugdar, Francisco Papalini, Ricardo Olocco, Gustavo Alberto Ferraris, Ignacio Magri, Daniel Lerda
Journal: Journal of Clinical Oncology (2013)

e13036 Background: Prognosis of patients with glioblastoma is based on clinical characteristics: age, performance status (PS), neurological deficit and extent of surgery. Two prognostic scores have been developed: Medical Research Council and RTOG scores. Molecular features of the tumor may also be accurate to determine the prognosis. Amplification of EGFR is found in 35% to 40% of patients, being more common as age increases. Researches of EGFR gene amplification by PCR and FISH have reported contradictory results. Methods: Research was carried out retrospectively to determine the prognostic value on survival of EGFR gene amplification by CISH in patients with glioblastoma, as well as age, extent of resection and post-surgery neurological PS. Results: EGFR gene amplification was analyzed in 42 patients. Average age: 56 years. 12 patients were under 50 years old and 30 patients were 50 years of age or older. 20 patients (48%) underwent complete resection, 10 patients (23%) partial resection and 12 patients (29%) biopsy. Of all patients, 12 (28.6%) had EGFR gene amplification. Only 1 of the 12 patients less than 50 years old presented amplification, while 11 of the 30 patients (36.6%) older than 50 years had such amplification. There were no significant differences in survival according to age groups, extent of resection and post-surgery neurological performance status. During follow-up, 11 of 12 patients (92%) with amplification died, while 20 of the 30 patients (67%) without amplification had died. There was a difference in survival with statistical significance for patients without EGFR gene amplification: equal test survival distributions for different levels of EGFR, Log Rank (Mantel-Cox) Chi Cuadrado 7,054, Gl 1,k, Sig 0,008. Conclusions: EGFR gene amplification in adult patients with glioblastoma negatively impacts patient survival.
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Authors: Michael S. Khodadoust, Alain H. Rook, Pierluigi Porcu, Francine Foss, Alison J. Moskowitz, Andrei Shustov, Satish Shanbhag, Lubomir Sokol, Steven P. Fling, Nirasha Ramchurren, Robert Pierce, Asa Davis, Richard Shine, Shufeng Li, Sophia Fong, Jinah Kim, Yi Yang, Wendy M. Blumenschein, Jennifer H. Yearley, Biswajit Das, Rajesh Patidar, Vivekananda Datta, Erin Cantu, Justine N. McCutcheon, Chris Karlovich, P. Mickey Williams, Priyanka B. Subrahmanyam, Holden T. Maecker, Steven M. Horwitz, Elad Sharon, Holbrook E. Kohrt, Martin A. Cheever, Youn H. Kim
Journal: Journal of Clinical Oncology (2019)

To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).
Incorporating Intimate Partner Violence Interventions in Nurse Home Visitation Programs
Authors: Leesa Hooker, Angela J. Taft
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal